Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Aptevo Therapeutics Inc. terminated Credit Agreement with MidCap Financial Trust with MidCap Financial Trust valued at Credit agreement terminated upon full repayment of all indebtedness (effective 2023-03-29).
- Action
- termination
- Agreement
- credit facility
- Counterparty
- MidCap Financial Trust
- Value
- Credit agreement terminated upon full repayment of all indebtedness
- Effective
- 2023-03-29
Exact text from the filing
On March 29, 2023, in connection with the closing of the Purchase Agreement, the Company repaid in full all indebtedness, liabilities and other obligations under, and terminated, that certain Credit Agreement by and between the Company and MidCap Financial Trust ("MidCap"), dated August 5, 2020 as amended from time to time.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Aptevo Therapeutics Inc. entered into Payment Interest Purchase Agreement with XOMA (US) LLC valued at $9,600,000 at closing plus up to $50,000 post-closing (effective 2023-03-29).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- XOMA (US) LLC
- Value
- $9,600,000 at closing plus up to $50,000 post-closing
- Effective
- 2023-03-29
Exact text from the filing
On March 29, 2023, the Company entered into and closed a payment interest purchase agreement (the "Purchase Agreement") with XOMA (US) LLC ("XOMA") pursuant to which the Company sold to XOMA its right, title and interest in and to all of the Deferred Payments and a portion of the Milestone Payments.
View on SEC.gov